437 related articles for article (PubMed ID: 12756828)
21. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
22. Company stock prices before and after public announcements related to oncology drugs.
Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
[TBL] [Abstract][Full Text] [Related]
23. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
24. Initial lessons from public-private partnerships in drug and vaccine development.
Wheeler C; Berkley S
Bull World Health Organ; 2001; 79(8):728-34. PubMed ID: 11545329
[TBL] [Abstract][Full Text] [Related]
25. Spending on new drug development1.
Adams CP; Brantner VV
Health Econ; 2010 Feb; 19(2):130-41. PubMed ID: 19247981
[TBL] [Abstract][Full Text] [Related]
26. What does R&D really cost?
Huff B
GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
[No Abstract] [Full Text] [Related]
27. Industry perspectives: ensuring vaccination of children and adolescents without financial barriers.
Feinberg MB; Gordon L
Pediatrics; 2009 Dec; 124 Suppl 5():S563-4. PubMed ID: 19948589
[No Abstract] [Full Text] [Related]
28. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
Glasziou PP
Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
[TBL] [Abstract][Full Text] [Related]
29. Global health. Public-private partnerships proliferate.
Cohen J
Science; 2006 Jan; 311(5758):167. PubMed ID: 16410497
[No Abstract] [Full Text] [Related]
30. The role of the private sector in biotechnology: research and development.
Feisee L
Health Matrix Clevel; 2002; 12(2):357-65. PubMed ID: 12430359
[No Abstract] [Full Text] [Related]
31. The important role of public-sector research in the United States.
Prescrire Int; 2013 Feb; 22(135):54. PubMed ID: 23444514
[TBL] [Abstract][Full Text] [Related]
32. Medicine. A portfolio model of drug development for tuberculosis.
Glickman SW; Rasiel EB; Hamilton CD; Kubataev A; Schulman KA
Science; 2006 Mar; 311(5765):1246-7. PubMed ID: 16513969
[No Abstract] [Full Text] [Related]
33. Public-private partnerships in health care for developing countries: a new paradigm for change.
Ahn M; Herman A; Damonti J
Manag Care Q; 2000; 8(4):65-72. PubMed ID: 11146847
[TBL] [Abstract][Full Text] [Related]
34. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
35. Public sector seeks to bridge 'valley of death'.
Moran N
Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
[No Abstract] [Full Text] [Related]
36. Firms seek new models to access public equity.
Mitchell P
Nat Biotechnol; 2009 Oct; 27(10):878-9. PubMed ID: 19816432
[No Abstract] [Full Text] [Related]
37. Attrition and translation.
Duyk G
Science; 2003 Oct; 302(5645):603-5. PubMed ID: 14576424
[TBL] [Abstract][Full Text] [Related]
38. Pharmaceutical research and development.
McKercher PL
Clin Ther; 1992; 14(5):760-4; discussion 759. PubMed ID: 1468093
[TBL] [Abstract][Full Text] [Related]
39. Downward pressure on US drug prices if Kerry wins.
Andrawiss M
Drug Discov Today; 2004 Oct; 9(20):861. PubMed ID: 15475314
[No Abstract] [Full Text] [Related]
40. Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA; Feldman L; Seckler A; Wilson A
Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
